Funding research is one of Sarcoma UK’s main charitable objectives.
Anyone donating to support Sarcoma UK’s research knows with certainty that their donation will help us fund patient-centred research into sarcoma.
Sarcoma UK funds only high quality research to understand more about sarcoma, find new treatments and ultimately identify a cure.
Since 2009, we have awarded over £1 million in scientific and medical grants to better understand these rare cancers. Our 2015 research investment is £350,000, our largest research call to date. All current and recent grant holders are both scientific and clinical researchers and reflect the broad spectrum of the research Sarcoma UK funds.
Our strategic goals are set out in our Research Strategy 2016-2020. The research we support covers all areas which add to the knowledge base in sarcoma, provide evidence to support changes to practice, and support potential breakthroughs to bring improvements to patients.
Excellent governance is at the heart of our research decision making.
We work closely with our Research Advisory Committee in setting a Research Strategy. The Research Advisory Committee sets the annual call specifications, and our Board of Trustees allocates the annual research investment.
All committee members and external peer reviewers are asked to declare any Conflicts of Interest.
Following peer review, the RAC will discuss and rank the applications for funding. Final approval comes from the Board of Trustees, and successful applicants are then notified and sent award letters.
Sarcoma UK is a member of the Association of Medical Research Charities (AMRC). All of our research is competitively and peer reviewed and any research funded by us is eligible for QR funding for UK Higher Education Institutions
The AMRC is a membership organisation of the leading medical and health research charities in the UK. Working with member charities and partners, they aim to support the sector’s effectiveness and advance medical research by developing best practice, providing information and guidance, improving public dialogue about research and science, and influencing government policy.
Sarcoma UK is a non-commercial partner of the National Institute of Health Research. This membership means that appropriate research studies funded by us are automatically eligible for NIHR Clinical Research Network (CRN) support. Projects funded get additional financial and practical support from this funding stream.
Our approach to Animal Research
As a member of the AMRC, we adhere to the principles of Animal Research agreed by the 133 constituent charities in the AMRC.
Aisling Burnand MBE, chief executive of the Association of Medical Research Charities said:
“Whether they are funding research using animals, or their funding is focused in other areas of medical research, all 133 AMRC member charities stand together in support of the principle of using animals in research when it is necessary to advance understanding of health and disease and to develop new treatments for patients. This research only takes place where there is no alternative available.
"The Concordat on Openness on Animal Research is a major statement of intent by the whole of the medical research community that openness and transparency over the use of animals for scientific research is non-negotiable. 85 organisations, including universities, charities, commercial companies, research councils, umbrella bodies and learned societies have signed. AMRC was closely involved in the development of the Concordat and, in signing, we signal the medical research charity sector’s united commitment to communicating openly about research involving animals.
"At the 2013 annual general meeting, our members unanimously agreed to link to the AMRC positon statement on the use of animals in research from their websites. We are working with our members to share best practice and ensure researchers exceed the regulatory requirements to improve animal welfare and science."